Article Sidebar

PDF
Issue: Vol. 567 No. 1 (2026)
Section: Các bài báo
DOI: 10.51298/vmj.v567i1.19291
Date Published: 05/11/2026
Views 38
Downloads 23
How to Cite
Châu, T. H., Cao, V. Đ., Phạm, K. T., Đoàn, T. T. T., & Phan, T. X. (2026). PREVALENCE AND DETECTION OF FLT3-ITD AND FLT3-D835Y MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA. Vietnam Medical Journal, 567(1). https://doi.org/10.51298/vmj.v567i1.19291

PREVALENCE AND DETECTION OF FLT3-ITD AND FLT3-D835Y MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Thúy Hà Châu1, , Văn Động Cao1, Kim Thạnh Phạm1, Thị Tuyết Thu Đoàn1, Thị Xinh Phan1,2
1 Bệnh viện Truyền máu Huyết học
2 Đại học Y Được Thành phố Hồ Chí Minh

Main Article Content

Abstract

Objectives: To determine the prevalence of FLT3-ITD and FLT3-D835Y using multiplex PCR combined with fragment analysis and compare detection with next-generation sequencing (NGS).


Results: The study included 154 newly diagnosed AML patients at the Blood Transfusion and Hematology Hospital from January to June 2026. Multiplex PCR combined with fragment analysis detected FLT3-ITD in 21 patients (13.64%) and FLT3-D835Y in five (3.25%); NGS detected these mutations in 12 (7.79%) and five (3.25%), respectively. Nine FLT3-ITD-positive cases were detected only by multiplex PCR combined with fragment analysis, representing 42.9% of cases positive by this method (p < 0.05). NGS additionally identified I867T, D835H and p.Ile836del in three other patients.


Conclusions: In this study, multiplex PCR combined with fragment analysis detected more FLT3-ITD-positive cases than the NGS workflow used, while NGS identified additional variants beyond D835Y. Combining both methods helps avoid missing mutations relevant to prognosis and treatment.

Keywords

FLT3-ITD, FLT3-D835Y, AML, Fragment analysis, NGS

Article Details

References

1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719.
2. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140(12):1345–1377.
3. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606.
4. Lee S, Sun CH, Jang H, et al. ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application. BMC Bioinformatics. 2023;24(1):62. doi:10.1186/s12859-023-05173-8.
5. Koga S, Du W, Yang G, Zhang L. Molecular Testing of FLT3 Mutations in Hematolymphoid Malignancies in the Era of Next-generation Sequencing. J Clin Transl Pathol. 2025;5(1):30-40. doi:10.14218/JCTP.2025.00008.
6. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. Journal of Molecular Diagnostics. 2003;5(2):96–102.
7. He R, Devine DJ, Tu ZJ, et al. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020;33(3):334-343. doi:10.1038/s41379-019-0359-9.
8. Kim JJ, Lee KS, Lee TG, Lee S, Shin S, Lee ST. A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication. Diagn Pathol. 2022;17(1):14. doi:10.1186/s13000-022-01202-x.
9. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with FLT3 mutation. New England Journal of Medicine. 2017;377(5):454–464.
10. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. New England Journal of Medicine. 2019;381(18):1728–1740.